English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, August 5, 2021
Eisai Receives Award for Excellence in Corporate Communications at the 37th Corporate Communications Awards
エーザイ、第37回企業広報賞「企業広報大賞」を受賞
Monday, August 2, 2021
Eisai's Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures
エーザイ、抗てんかん剤「フィコンパ(R)」が中国において部分てんかんの単剤療法および小児適応に係る承認を取得
Friday, July 30, 2021
エーザイとバイオジェン、アルツハイマー病の初めてのリアルワールド観察臨床第IV相試験となるADUHELM ICARE AD-USの試験デザインをアルツハイマー病協会国際会議2021において発表
エーザイ、社会的責任投資指数「FTSE4Good Index Series」の対象銘柄に20年連続で選定
エーザイとバイオジェン、Lecanemab(BAN2401)の臨床効果についてアルツハイマー病協会国際会議2021(AAIC2021)のLate Breakingとして発表
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401)
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer's Disease at AAIC 2021
Thursday, July 29, 2021
Eisai Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for Socially Responsible Investment

Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575